Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals - China, 2022

China CDC Wkly. 2023 Dec 29;5(52):1155-1160. doi: 10.46234/ccdcw2023.217.

Abstract

What is already known about this topic?: Bacterial resistance surveillance is crucial for monitoring and understanding the trends and spread of drug-resistant bacteria.

What is added by this report?: The number of strains collected in 2022 increased compared to 2021. The top five bacteria, including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii, remained largely unchanged. The detection rate of methicillin-resistant strains continued to decrease. Among clinical Enterobacterales isolates, the resistance rate to carbapenems was generally below 13%, except for Klebsiellaspp., which had a resistance range of 20.4% to 21.9%. Most clinical Enterobacterales isolates were highly susceptible to tigecycline, colistin, and polymyxin B, with resistance rates ranging from 0.1% to 12.6%. The detection rate of meropenem-resistant P. aeruginosa and meropenem-resistant Acinetobacter baumannii showed a decreasing trend for the fourth consecutive year.

What are the implications for public health practice?: Multidrug-resistant bacteria remain a significant public health challenge in clinical antimicrobial treatment. To effectively address bacterial resistance, it is essential to enhance both bacterial resistance surveillance and the prudent use of antimicrobial agents.

Keywords: Antimicrobial susceptibility testing; Bacterial resistance surveillance; Carbapenem-resistant gram-negative bacilli; Methicillin-resistant S. aureus.

Grants and funding

This research was supported by the National Key Research and Development Program of China (2021YFC2701800 and 2021YFC2701803), the China Antimicrobial Surveillance Network (funding from Pfizer, 2023QD020), and the Shanghai Antimicrobial Surveillance Network (3030231003)